Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2021-02-05 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2021-02-05 English
6-K
Foreign Filer Report
2021-01-29 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details a positive opinion received from the CHMP (Committee for Medicinal Products for Human Use) regarding a drug (ofatumumab). It includes key financial/operational updates related to regulatory milestones and clinical trial results, but it is not a full annual report (10-K), an interim report (IR), or a formal earnings release (ER). It is a specific, material announcement intended for investors and the public regarding a significant regulatory step. Since it is a general, material announcement that doesn't fit the highly specific categories like DIV, DIRS, or MANG, the most appropriate classification is the general regulatory announcement fallback, RNS (Regulatory Filings). The document length (9971 chars) is substantial enough that it is not merely an announcement *about* a report (RPA), but the report/release itself.
2021-01-29 English
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from Genmab A/S regarding a positive opinion from the CHMP (EMA) for a drug candidate. It follows the standard format of a press release/regulatory announcement. While it mentions an attachment, the text itself provides the full details of the announcement, making it a primary regulatory filing rather than just a notification of a report. It does not fit into specific categories like 10-K, Earnings Release, or M&A, so it falls under the general regulatory announcement category.
2021-01-29 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is titled 'Company Announcement' and details a specific corporate event: the Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion recommending marketing authorization for a drug (Ofatumumab). This is a material, non-financial update concerning regulatory progress and partnership activities. It is not a full Annual Report (10-K), an Earnings Release (ER), an Interim Report (IR), or a formal Investor Presentation (IP). Since it is a specific, material announcement that doesn't fit the other specialized categories (like DIRS, DIV, CAP, etc.), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a catch-all for significant regulatory news that isn't a standard financial report or a specific insider/dividend/M&A event. The document length is substantial (nearly 10,000 characters), so it is the announcement itself, not just a notice of publication (RPA).
2021-01-29 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-01-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.